Capricor Therapeutics Announces Formation of Duchenne Muscular Dystrophy Advisory Board – PR Newswire (press release)

Barry Byrne, M.D., Ph.D.

University of Florida (USA)

Michelle Eagle, Ph.D., M.Sc., MCSP

Atom International Ltd (UK)

Richard Finkel, M.D.

Nemours Children's Hospital (USA)

Pat Furlong

Parent Project Muscular Dystrophy (USA)

Kan Hor, M.D.

Nationwide Children's Hospital (USA)

John Jefferies, M.D.

Cincinnati Children's Hospital Medical Center (USA)

Oscar Henry Mayer, M.D.

Children's Hospital of Philadelphia (USA)

Eugenio Mercuri, M.D., Ph.D.

Catholic University of the Sacred Heart (Italy)

Francesco Muntoni, M.D.

University College London (UK)

Ron Victor, M.D.

Cedars-Sinai Medical Center (USA)

Thomas Voit, M.D.

University College London (UK)

Linda Marbn, Ph.D., president and CEO of Capricor, said, "We are gratified to have the attention and support of some of the foremost thought leaders in Duchenne muscular dystrophy, several of whom we have been working with since last fall. Following our recent announcement of positive clinical data in DMD with CAP-1002, we have formalized these relationships by assembling what we believe is a world-class advisory board of Duchenne specialists."

"With their collaboration, we are planning the next steps in CAP-1002's development in DMD, including the design of a randomized, double-blind, placebo-controlled clinical trial of intravenous, repeat-dose CAP-1002 in which we expect to begin patient enrollment in the latter half of this year, subject to regulatory approval," added Dr. Marbn.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other medical conditions. Capricor's lead candidate, CAP-1002, is a cell-based candidate currently in clinical development for the treatment of Duchenne muscular dystrophy, myocardial infarction (heart attack), and heart failure. Capricor is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. For more information, visit http://www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on March 16, 2017, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with prospectus supplements thereto, and in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on May 15, 2017. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. Capricor's exosomes technology, including CAP-2003, has not yet been approved for clinical investigation.

For more information, please contact:

AJ Bergmann, Vice President of Finance +1-310-358-3200 abergmann@capricor.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/capricor-therapeutics-announces-formation-of-duchenne-muscular-dystrophy-advisory-board-300463679.html

SOURCE Capricor Therapeutics, Inc.

http://capricor.com

Read more here:
Capricor Therapeutics Announces Formation of Duchenne Muscular Dystrophy Advisory Board - PR Newswire (press release)